Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib

被引：2
作者：
Huang Yi-sheng [1 ]
Huang Biao [2 ]
Wu Yi-long [1 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Gen Hosp, Dept Radiol, Guangzhou 510080, Guangdong, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2011年 / 124卷 / 22期
关键词：
gefitinib; leukoencephalopathy; radiosensitizing; non-small cell lung cancer; RECEPTOR-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; RADIATION; BRAIN; INHIBITOR; NEUROTOXICITY; CHEMOTHERAPY; METHOTREXATE; RADIOTHERAPY; SURVIVAL;
D O I：
10.3760/cma.j.issn.0366-6999.2011.22.043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The present case is a patient with advanced non-small cell lung cancer (NSCLC) who developed leukoencephalopathy following radiotherapy and gefitinib treatments. There are rarely reports of such incidences because the median survival period of advanced NSCLC is only ten months. The features of leukoencephalopathy in this case were atypical for radiation leukoencephalopathy, so it was suspected that the leukoencephalopathy was associated with gefitinib. Chin Med J 2011;124(22):3834-3837
引用
收藏
页码：3834 / 3837
页数：4
相关论文
共 50 条
  • [1] Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
    Nakamura, Yoichi
    Sano, Kazumi
    Soda, Hiroshi
    Takatani, Hiroshi
    Fukuda, Minoru
    Nagashima, Seiji
    Hayashi, Tomayoshi
    Oka, Mikio
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) : 1404 - 1409
  • [2] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [3] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [4] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [5] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [6] Personalized treatment of advanced non-small cell lung cancer
    Koehler, J.
    Schuler, M.
    ONKOLOGE, 2011, 17 (08): : 702 - +
  • [7] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [8] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    Chen Min-jiang
    Zhong Wei
    Zhang Li
    Zhao Jing
    Li Long-yun
    Wang Meng-zhao
    CHINESE MEDICAL JOURNAL, 2013, 126 (12) : 2235 - 2241
  • [9] Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer
    Araya, Tomoyuki
    Kasahara, Kazuo
    Demura, Yoshiki
    Matsuoka, Hiroki
    Nishitsuji, Masaru
    Nishi, Koichi
    LUNG CANCER, 2013, 80 (03) : 344 - 346
  • [10] Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Zheng, Aimin
    Huang, Guanghui
    Li, Wenhong
    Ni, Xiang
    Wang, Jiao
    Han, Xiaoying
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 38 (01) : 135 - 142
12345